Effect of AIV007 by Periocular Administration in Subjects With nAMD or DME
Status:
Not yet recruiting
Trial end date:
2025-04-06
Target enrollment:
Participant gender:
Summary
To determine safety, pharmacokinetics, and duration of effect of periocularly administered
AIV007 gel suspension in subjects with neovascular age-related macular degeneration (nAMD) or
diabetic macular edema (DME).